Avior Bio

company

About

Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$256K
Industries
Biotechnology,Neuroscience,Pharmaceutical,Product Design
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$256K
Avior Bio has raised a total of $256K in funding over 2 rounds. Their latest funding was raised on Jul 1, 2021 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 1, 2021 Grant $256K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Avior Bio is funded by 1 investors. National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant